The National
Expensive CAR T-cell immunotherapy could plummet in price to bring life-saving care to the masses
Cancer drugs costing more than $1 million could be drastically reduced in price by changes to the way immunotherapies are produced, opening up new opportunities for life-saving care.
Novel CAR T-cell therapies offering bespoke treatments are some of the most expensive to produce and deliver, making them out of reach the majority of patients.
The basic cost to deliver the therapy is at least $350,000, with additional licensing fees and other hospital expenses often pushing prices beyond the $1m mark.
